Nyrada

Media


 
    Nyrada Inc (ASX:NYR) Advances Phase I Clinical Trial to Third Cohort  
 
    Nyrada's Neuroprotective Drug Advances With Key Partnerships  
 
    Nyrada doses first cohort in trial to assess neuroprotective, cardioprotective drug  
 
    These ASX companies are stepping up to tackle traumatic brain injury head-on  
 
    Nyrada raises $3.36 million to support drug discovery  
 
    Nyrada says it has completed safety studies ahead of Phase 1 clinical trial  
 
    Health Check: Rats – and investors – are happy as Nyrada forges ahead with its first human brain injury trial  
 
    Nyrada gears up for Phase I clinical trials  
 
    Tony’s Takeaway: Biotech buffet on the ASX - Stockhead TV  
 
    Nyrada progresses brain injury programme studies  
 
    Bulls'n'Bears ASX Runners of the Week  
 
    Nyrada’s NYR-BI03 shows significant cardioprotective efficacy in preclinical study  
 
    Nyrada Shares Surge After Lead Drug Candidate Demonstrates Significant Cardioprotection  
 
    Nyrada’s NYR-BI03 shows safety in rats; Phase I planned for late 2024  
 
    ‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2  
 
    4 of the best performing pharma & biotech stocks to begin the new year  
 
    The next Neuren? Nyrada chases after two big markets  
 
    This week’s Bulls N’ Bears top ASX runner is … Nyrada.  
 
    Guess which ASX pharmaceuticals stock is up 400% in 2 days  
 
    Nyrada CEO exclusively shares 3 reasons for stunning +420pc session  
 
    Biotech Dispatch: Nyrada reports 'encouraging' early efficacy results from PCSK9i program  

Australian biotech news website, BiotechDispatch said Nyrada had reported "encouraging efficacy results" from an in vivo study involving its NYX-PCSK9i drug candidate.

Read more here

 
    Nyrada (ASX: NYR) CEO James Bonnar discusses the company’s commercialisation plans  
 
    Hypercholesterolaemia Drug Candidate Animation  
 
    Nyrada Brain Injury Explainer Animation